



Dr. med. Christian Öhlschlegel

Kontakt

Dr. med. Christian Öhlschlegel
Rorschacher Strasse 95
9007 St.Gallen
Switzerland

T +41 71 494 2104
christian.oehlschlegel@kssg.ch

Homepage

www.pathologie-kssg.ch

Bereiche

Pathologie

Funktion

Leitende(r) Arzt/Ärztin

Publikationen (40)

Erschbamer M, Zdravkovic V, Erhardt J, Öhlschlegel C, Grob K. Osteolytic changes around biodegradable cement restrictors in hip surgery. *Acta Orthop* 2016;1-6.

Saladin C, Kubik-Huch R, Stadlmann S, Rageth C, Rageth L, Seifert B, Öhlschlegel C, Kampmann G, Haueisen H. Lesions with unclear malignant potential (B3) after minimally invasive breast biopsy: evaluation of vacuum biopsies performed in Switzerland and recommended further management. *Acta Radiol* 2015; 57:815-21.

Regan M, Sessa F, Peg Cámaras V, Rodríguez Peralto J, MacGrogan G, Colleoni M, Goldhirsch A, Price K, Coates A, Gelber R, Viale G, Öhlschlegel C, Pizzolitto S, Pagani O, Francis P, Fleming G, Walley B, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, SOFT and TEXT Investigators and International Breast Cancer Study Group. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. *Breast Cancer Res Treat* 2015

Mukherjee R, Öhlschlegel C, Litschel R. [Orbital mass in a 23 years old male patient]. *Laryngorhinootologie* 2015; 94:690-1.

Knechtle B, Jäckel K, Rosemann T, Rüst C, Öhlschlegel C. [My Back is Still Hurting!]. *Praxis (Bern 1994)* 2015; 104:581-6.

Varga Z, Cassoly E, Li Q, Öhlschlegel C, Tapia C, Lehr H, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. *PLoS one* 2015; 10:e0123435.

Koehle O, Abt D, Rothermundt C, Öhlschlegel C, Brugnolaro C, Schmid H. Soft tissue sarcomas of the kidney. *Rare Tumors* 2015; 7:5635.

Collaud S, Tischler V, Atanassoff A, Wiedl T, Komminoth P, Öhlschlegel C, Weder W, Soltermann A. Lung neuroendocrine tumors: correlation of ubiquitylation and sumoylation with nucleo-cytosolic partitioning of PTEN. *BMC cancer* 2015; 15:74.

Schmid S, Öhlschlegel C, Nagel W, Zeisel C, Müller J, Rothermundt C. Pulmonary embolism in a patient with primary renal synovial sarcoma: the important differential diagnosis of tumor embolism and its therapeutic implications. *Case Rep Oncol* 2013; 6:331-8.

Öhlschlegel C, Kradolfer D, Hell M, Jochum W. Comparison of automated and manual FISH for evaluation of HER2 gene status on breast carcinoma core biopsies. *BMC Clin Pathol* 2013; 13:13.

AGO, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Gruber G, Öhlschlegel C, DGS, SGS, ÖGS, Panelists, Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Peintinger F. German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer. *Eur J Cancer* 2013; 49:2277-83.

Huober J, Regan M, Gelber R, Price K, Öhlschlegel C, Viale G, Coates A, Goldhirsch A, Gelber S, Thürlimann B. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. *Ann Oncol* 2012; 23:2843-51.

Varga Z, Viale G, Mastropasqua M, Wagner U, Tapia C, Singer G, Schreiber-Facklam H, Schobinger-Clement S, Sancho Oliver S, Rakozy C, Padberg B, Öhlschlegel C, Obermann E, Noske A, Kaup D, Frick H, Dommann-Scherrer C, Diebold J, Lehr H. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. *PLoS one* 2012; 7:e37379.

Sawatzki M, Stienen M, Straumann A, Meyenberger C, Öhlschlegel C, Binek J. Endoscopic treatment of paraesophageal abscess in eosinophilic esophagitis after chest trauma. *Gastrointest Endosc* 2011

Öhlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W. HER2 genetic heterogeneity in breast carcinoma. *J Clin Pathol* 2011; 64:1112-6.

Varga Z, Moch H, Jochum W, Bosshard G, Kradolfer D, Noske A, Sun Y, Wang Z, Tubbs R, Öhlschlegel C. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. *Breast Cancer Res Treat* 2011

Bolla D, Bolla N, Öhlschlegel C, Schoening A, Stickel J, Thürlimann B, Hornung R. Pseudoangiomatous stromal hyperplasia of breast in man: a case report. *Breast J* 2011; 17:311-2.

Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). *Endocr Relat Cancer* 2011; 18:257-64.

Öhlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W. [Intratumoral heterogeneity of HER2 status in breast carcinoma]. *Pathologe* 2010; 31 Suppl 2:292-5.

Hengartner H, Öhlschlegel C. Sinus Histiocytosis with massive lymphadenopathy (Rosai-Dorfman-disease) treated with Cladribine (2-CdA). *Schweizer Krebsbulletin - Bulletin suisse du cancer* 2009; 29:312-314.

Boneberg E, Senn H, Otto F, Dupont-Lampert V, Beer G, Füzesi L, Steininger H, Öhlschlegel C, Hoefer M, Legler D, Fürstenberger G. Angiogenesis and lymphangiogenesis are downregulated in primary breast cancer. *Br J Cancer* 2009; 101:605-14.

Fokt R, Templeton A, Gillessen Sommer S, Öhlschlegel C, Schmid H. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib. *Urol Int* 2009; 83:122-4.

Viale G, Goldhirsch A, Gelber R, Öhlschlegel C, Karlsson P, Crivellari D, Golouh R, Brown R, Price K, Regan M, Castiglione-Gertsch M, Colleoni M, Mallon E, Sonzogni A, Mastropasqua M, Maiorano E, Gusterson B, Giobbie-Hurder A, Coates A. Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer. *Ann Oncol* 2009; 21:245-54.

Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Braye S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. *J Clin Oncol* 2008; 26:5569-75.

Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Rusca T, Grigolato P, Braye S, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Mastropasqua M, Maiorano E, Regan M, Coates A. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. *J Clin Oncol* 2008; 26:1404-10.

Viale G, Coates A, Goldhirsch A, Gelber R, Castiglione-Gertsch M, Gusterson B, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Price K, Colleoni M, Maiorano E, Maffini F, Mastropasqua M, Regan M, International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. *J Natl Cancer Inst* 2008; 100:207-12.

Witteck A, Öhlschlegel C, Boggian K. Delayed diagnosis of atypical mycobacterial skin and soft tissue infections in non-immunocompromized hosts. *Scand J Infect Dis* 2008; 40:877-80.

Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlmann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. *J Clin Oncol* 2007; 25:3846-52.

Staub-Zähner T, Garzoni D, Fretz C, Lampert C, Öhlschlegel C, Wüthrich R, Fehr T. Pseudotumor of gout in the patella of a kidney transplant recipient. *Nat Clin Pract Nephrol* 2007; 3:345-9.

Senn Bahls E, Dupont Lampert V, Öhlschlegel C, Senn H. Multitarget stereotactic core-needle breast biopsy (MSBB)--an effective and safe diagnostic intervention for non-palpable breast lesions: a large prospective single institution study. *Breast* 2006; 15:339-46.

Hungermann D, Buerger H, Öhlschlegel C, Herbst H, Boecker W. Adenomyoepithelial tumours and myoepithelial carcinomas of the breast—a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cells. *BMC cancer* 2005; 5:92.

Varga Z, Zhao J, Öhlschlegel C, Odermatt B, Heitz P. Preferential HER-2/neu overexpression and/or amplification in aggressive histological subtypes of invasive breast cancer. *Histopathology* 2004; 44:332-8.

Mihic-Probst D, Zhao J, Saremaslani P, Baer A, Öhlschlegel C, Paredes B, Komminoth P, Heitz P. CGH analysis shows genetic similarities and differences in atypical fibroxanthoma and undifferentiated high grade pleomorphic sarcoma. *Anticancer Res* 2004; 24:19-26.

Hurschler D, Borovicka J, Neuweiler J, Öhlschlegel C, Sagmeister M, Meyenberger C, Schmid U. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma. *Swiss medical weekly : official journal of the Swiss Society of Infectious Diseases, the Swiss Society of Internal Medicine, the Swiss Society of Pneumology* 2003; 133:507-14.

von Büren T, Peter B, Öhlschlegel C, Grossenbacher R. [Deglutition problems and dyspnea with stridor. Cervical high-grade type osteosarcoma, apparently of extraskeletal origin]. *HNO* 2003; 51:912-4.

Jörger M, Öhlschlegel C, Cerny T, Gillessen Sommer S. Postradiation high-grade myofibroblastic sarcoma of the prostate -- a rare entity of prostatic tumors -- responding to liposomal Doxorubicin. *Onkologie* 2002; 25:558-61.

Ward J, Jeanneret B, Öhlschlegel C, Magerl F. The value of percutaneous transpedicular vertebral bone biopsies for histologic examination. Results of an experimental histopathologic study comparing two biopsy needles. Spine 1996; 21:2484-90.

Eisterer W, Neyer U, Hilbe W, Diem G, Öhlschlegel C, Ludescher C, Thaler J. Effect of cyclosporin A in a patient with refractory nephrotic syndrome associated with B chronic lymphocytic leukemia. Nephron 1996; 72:468-71.

Hürlimann R, Binek J, Öhlschlegel C, Hammer B. [Enalapril (Reniten)-associated toxic hepatitis]. Schweizerische medizinische Wochenschrift 1994; 124:1276-80.

Wehrmann M, Bohle A, Bogenschütz O, Eissele R, Freislederer A, Öhlschlegel C, Schumm G, Batz C, Gärtner H. Long-term prognosis of chronic idiopathic membranous glomerulonephritis. An analysis of 334 cases with particular regard to tubulo-interstitial changes. Clin Nephrol 1989; 31:67-76.

Projekte (4)

Verteilung der Werte des Proliferationsmarkers Ki-67 am Kantonsspital St.Gallen

Klinische Forschung - 15.10.2014 - 26.09.2015

Abgeschlossen

A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer

Klinische Forschung - 01.05.2013 - 01.05.2019

Automatisch geschlossen

SAKK 22/10: A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer

Klinische Forschung - 29.04.2013 - 27.06.2015

Automatisch geschlossen

Randomisierte Phase III Studie zu Bestrahlungsdosens und Fraktionierungsschemata bei duktalem Carcinoma in situ (DCIS) der Brust mit mittlerem und hohem Rückfallrisiko

Klinische Forschung - 02.11.2010 - 31.12.2015

Automatisch geschlossen